VP, Digital Health Technology and Data Services
Philip Ma is Vice-President of Digital Health Technology and Data Sciences at Biogen, a global biopharmaceutical company, focused on the discovery, development, manufacturing, and delivery of therapies for neurological, autoimmune and hematologic disorders. In his role, Philip is responsible for sourcing, developing, and applying transformative digital technologies and advanced data analyses to discover insights and create value for Biogen, and its patients, providers and payers. Philip and his team have developed leading capabilities in data sciences, data engineering, digital product development, digital customer insights, external technology partnering, and project management, and apply these capabilities across the broader Biogen organization, from research through to commercial functions.
Prior to joining Biogen, Philip Ma was a Director (senior partner) in the Silicon Valley Office of McKinsey & Company, the world’s leading management consulting firm serving 70% of the Fortune 1000, and many leading global public institutions. Philip served health care clients in the U.S., Europe, and Japan, generally in the Fortune 500, focused on leading players in the pharmaceuticals, biotechnology, and medical products sectors on a variety of strategic, organizational, and operational issues.
Active in community affairs, Philip served on the board of directors for the United Way of Silicon Valley for 10 years. Philip is also a current member of Committee of 100, a group of Chinese-American business and community leaders focused on US-China relations and the role of Asians in the U.S.
Prior to joining McKinsey, Philip worked as a research scientist in the Department of Biology at the Massachusetts Institute of Technology, where he was involved in studying the atomic structures of proteins involved in gene regulation, using X-ray crystallography.
Philip holds a Ph.D. in biology from the Massachusetts Institute of Technology, an M.Phil. degree in economics from Oxford University, where he was a Rhodes Scholar, and an A.B. degree in biochemistry from Harvard University